MDGL
Madrigal Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$541.08
−0.28%Margins
Gross margin
91.5%
EBITDA margin
-23.3%
EBIT margin
-25.1%
Net margin
-25.3%
FCF margin
-16.1%
-62.1%
Return on equity
-26.1%
Return on assets
-37.0%
Return on invested capital
1.04x
Asset turnover
-$197.7M
Cash from operations
$36
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026